OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Pharmacokinetics and Pharmacodynamics is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-03-01 to 2025-03-01.)

Article	Citations
Thanks to our reviewers 2021!	82
A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson’s disease: application to preladenant	38
Application of different approaches to generate virtual patient populations for the quantitative systems pharmacology model of erythropoiesis	37
Reliability of in vitro data for the mechanistic prediction of brain extracellular fluid pharmacokinetics of P-glycoprotein substrates in vivo; are we scaling correctly?	33
No QT interval prolongation effect of sepiapterin: a concentration-QTc analysis of pooled data from phase 1 and phase 3 studies in healthy volunteers and patients with phenylketonuria	32
The Finite Absorption Time (FAT) concept en route to PBPK modeling and pharmacometrics	28
Authors’ response to letter to editor	27
A next generation mathematical model for the in vitro to clinical translation of T-cell engagers	22
Achieving big with small: quantitative clinical pharmacology tools for drug development in pediatric rare diseases	21
Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies	18
Population pharmacokinetic and pharmacokinetic-pharmacodynamic modeling of bempedoic acid and low-density lipoprotein cholesterol in healthy subjects and patients with dyslipidemia	18
Development of PBPK model for intra-articular injection in human: methotrexate solution and rheumatoid arthritis case study	16
Correction to: R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Op	14
Understanding virtual patients efficiently and rigorously by combining machine learning with dynamical modelling	12
PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data	12
Reduction of quantitative systems pharmacology models using artificial neural networks	11
Variability and uncertainty: interpretation and usage of pharmacometric simulations and intervals	11
Should patients skip late doses of medication? A pharmacokinetic perspective	10
Concentration-QTc analysis with two or more correlated baselines	9
Applications of cosinor rhythmometry in pharmacology	9
From data to QSP models: a pipeline for using Boolean networks for hypothesis inference and dynamic model building	9
Population pharmacokinetic and pharmacodynamic model of propofol externally validated in Korean elderly subjects	8
A quantitative systems pharmacology model of plasma kallikrein-kinin system dysregulation in hereditary angioedema	8
Learning pharmacometric covariate model structures with symbolic regression networks	8
Time Scale Calculus: a new approach to multi-dose pharmacokinetic modeling	8

Correction: External control arms for rare diseases: building a body of supporting evidence	7
Mechanistic incorporation of FcRn binding in plasma and endosomes in a whole body PBPK model for large molecules	7
Systemic exposure following intravitreal administration of therapeutic agents: an integrated pharmacokinetic approach. 2. THR-687	7
Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019–2023) by US FDA, best practices and recommendations	7
Correction to: Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	7
Population pharmacokinetic/pharmacodynamic modeling of nifekalant injection with varies dosing plan in Chinese volunteers: a randomized, blind, placebo-controlled study	7
Empirical bayes approach for dynamic bayesian borrowing for clinical trials in rare diseases	7
Likelihood comparisons in bounded outcome score analysis must be internally consistent	7
Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice	7
Individualized optimization of colistin loading doses	7
Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of	6
A review of the physiological effects of microgravity and innovative formulation for space travelers	6
Model-informed approach to estimate treatment effect in placebo-controlled clinical trials using an artificial intelligence-based propensity weighting methodology to account for non-specific responses	6
Recommendations for a standardized publication protocol for a QSP model	6
Virtual clinical trials via a QSP immuno-oncology model to simulate the response to a conditionally activated PD-L1 targeting antibody in NSCLC	6
Novel endpoints based on tumor size ratio to support early clinical decision-making in oncology drug-development	6
Current practices for QSP model assessment: an IQ consortium survey	6
Translational population target binding model for the anti-FcRn fragment antibody efgartigimod	6
An integrated modelling approach for targeted degradation: insights on optimization, data requirements and PKPD predictions from semi- or fully-mechanistic models and exact steady state solutions	6
Joint longitudinal model-based meta-analysis of FEV1 and exacerbation rate in randomized COPD trials	5
A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration	5
Evaluation of covariate effects using variance-based global sensitivity analysis in pharmacometrics	5
Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)	5
Clinical validation of translational antibody PBPK model using tissue distribution data generated with 89Zr-immuno-PET imaging	5
Implementation of non-linear mixed effects models defined by fractional differential equations	5
Predicting efficacy assessment of combined treatment of radiotherapy and nivolumab for NSCLC patients through virtual clinical trials using QSP modeling	5
Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasis	5
A two-stages global sensitivity analysis by using the δ sensitivity index in presence of correlated inputs: application on a tumor growth inhibition model based on the dynamic energy budget theory	5
Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations	4
Generation and application of avatars in pharmacometric modelling	4
Optimum multi-drug regime for compartment model of tumour: cell-cycle-specific dynamics in the presence of resistance	4
Analysis of cellular kinetic models suggest that physiologically based model parameters may be inherently, practically unidentifiable	4
Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease	4
Mixed effect estimation in deep compartment models: Variational methods outperform first-order approximations	4
A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy	4
Wide size dispersion and use of body composition and maturation improves the reliability of allometric exponent estimates	4
A population pharmacokinetics model of balovaptan to support dose selection in adult and pediatric populations	4
A PopPBPK-RL approach for precision dosing of benazepril in renal impaired patients	4
Visual predictive check of longitudinal models and dropout	4